mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD).
Shernan G
SG
Holtan
Luis F
LF
Porrata
Joseph P
JP
Colgan
Clive S
CS
Zent
Thomas M
TM
Habermann
Svetomir N
SN
Markovic
D000368:Aged; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011494:Protein Kinases; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases; D017211:Treatment Failure; D014766:Viremia / Q000188:drug therapy*
D016756:Immunoglobulins, Intravenous; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus; D008775:Methylprednisolone